Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis

“…During inflammation, the receptor induces cell activation by initiating intracellular signalling cascades [10,55] resulting in rapid gene transcription [56] . RAGE is upregulated in various inflammatory diseases, such as rheumatoid arthritis [57,58] , inflammatory kidney disease [59,60] , arteriosclerosis [61] and inflammatory [71,72] . Presepsin is a promising biomarker for diagnosing sepsis, severe sepsis and septic shock compared to other biomarkers such as PCT [73][74][75][76] and seems specific for infectious diseases [71] .…”

Section: Soluble Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

“…Presepsin is a promising biomarker for diagnosing sepsis, severe sepsis and septic shock compared to other biomarkers such as PCT [73][74][75][76] and seems specific for infectious diseases [71] . High plasma levels in septic patients can be detected 6 h after early onset [72] . A recent study demonstrated that measurements of presepsin levels revealed diagnostic and prognostic value in patients with severe sepsis and septic shock within the first week of ICU treatment.…”

Section: Soluble Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Kojic

Siegler

Uhle

et al. 2015

WJEM

View full text Add to dashboard Cite

Beside many efforts to improve outcome, sepsis is still one of the most frequent causes of death in critically ill patients. It is the most common condition with high mortality in intensive care units. The complexity of the septic syndrome comprises immunological aspects -i.e. , sepsis induced immunosuppression -but is not restricted to this fact in modern concepts. So far, exact mechanisms and variables determining outcome and mortality stay unclear. Since there is no typical risk profile, early diagnosis and risk stratification remain difficult, which hinders rapid and effective treatment initiation. Due to the heterogeneous nature of sepsis, potential therapy options should be adapted to the individual. Biomarkers like C-reactive protein and procalcitonin are routinely used as complementary tools in clinical decision-making. Beyond the acute phase proteins, a wide bunch of promising substances and non-laboratory tools with potential diagnostic and prognostic value is under intensive investigation. So far, clinical decision just based on biomarker assessment is not yet feasible. However, biomarkers should be considered as a complementary approach. Core tip: Sepsis is a complex continuum of disturbed systems. Despite the presence of clinical consensus criteria, the early diagnosis especially in the perioperative setting is challenging. A magnitude of potential new biomarkers is tested for this purpose, but evidence is mounting that due to the complex nature of the syndrome, biomarkers are rather complementary tools for clinical decision making than "magic bullets". Moreover, biomarkers are also evaluated for therapy guidance, linking diagnostic results to an individual therapeutic regime. This review summarizes the developments in the biomarker field, aiming to provide an overview about current targets and their limitations.

show abstract

“…Upon monocyte activation, CD14 is shed from the cell membrane and circulates as soluble CD14 (sCD14), which exists in two molecular forms (55 kDa and 49 kDa). During activation and shedding of CD14 from the cell surface membrane, one molecule sCD14 is split into approximately four molecules of the 13 kDa fragment sCD14-ST [5].…”

Section: Introductionmentioning

confidence: 99%

Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department

Carpio

Zapata

Spanuth

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department, Clinica Chimica Acta (2015), doi: 10.1016/j.cca.2015.08.013 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. AbstractBackground: Presepsin (PSEP) is released during infectious diseases and can be

show abstract

Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis

Cited by 274 publications

References 16 publications

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department

Contact Info

Product

Resources

About